Correction: Standards Without Labs: Drug Development in the Psychedelic Underground

JOHN BAILEY D JOANNA KEMPNER D

*Author affiliations can be found in the back matter of this article

CITIZEN SCIENCE: THEORY AND PRACTICE

CORRECTION

]u[ubiquity press

ABSTRACT

This article details a correction to: Bailey, J. and Kempner, J., 2022. Standards Without Labs: Drug Development in the Psychedelic Underground. *Citizen Science: Theory and Practice*, 7(1), p. 41. DOI: http://doi.org/10.5334/cstp.527.

This article has been corrected here: https://doi.org/10.5334/ cstp.527

CORRESPONDING AUTHOR: John Bailey

Rutgers University, US jbailey@sociology.rutgers.edu

KEYWORDS:

Citizen science; pharmaceuticals; drug development; psilocybin; psychedelics; standardization

TO CITE THIS ARTICLE:

Bailey, J and Kempner, J. 2023. Correction: Standards Without Labs: Drug Development in the Psychedelic Underground. *Citizen Science: Theory and Practice*, 8(1): 49, pp. 1–2. DOI: https://doi.org/10.5334/ cstp.647

CORRECTION

Bailey and Kempner (2022) mention that "the patent issued for the use of psilocybin as a therapy for cluster headache by the US Patent and Trademark Office fails to include the names of anyone affiliated with Clusterbusters (**Sewell 2014**)." Sewell (2014) draws upon Clusterbusters' experience using psilocybin without citation but does not attempt to patent this knowledge. Schindler and D'Souza (2021) is an example of a patent application filed for using psilocybin as a therapy for cluster headache that failed to include the names of anyone affiliated with Clusterbusters.

COMPETING INTERESTS

The authors received a small grant from Porta Sophia, a non-profit psychedelic prior art library that submitted a third-party preissuance to the United States Patent and Trademark Office (USPTO) in reference to the application, US Pat. App. Ser. No. 17/168,638 entitled "Psychedelic Treatment for Headache Disorders."

AUTHOR AFFILIATIONS

John Bailey ⁽¹⁾ orcid.org/0000-0003-4265-1680 Rutgers University, US

Joanna Kempner D orcid.org/0000-0002-9784-6381 Rutgers University, US

REFERENCES

- Bailey, J and Kempner, J. 2022. Standards Without Labs: Drug Development in the Psychedelic Underground. *Citizen Science: Theory and Practice*, 7(1): 41. DOI: http://doi. org/10.5334/cstp.527
- Sewell, RA. 2014. Compositions and methods for preventing and/or treating disorders associated with cephalic pain. US Patent. Available at: https://patentimages. storage.googleapis.com/4a/71/f0/384eb6c7b7aa05/ US8859579.pdf (Accessed 15 August 2022).
- Schindler, E and D'Souza, D. 2021. Psychedelic Treatment for Headache Disorders. USPTO 20210236523:A1. US Patent, filed February 5, 2021, and issued August 5, 2021. https://patentimages.storage.googleapis.com/14/ d8/57/275bba56b2588b/US20210236523A1.pdf.

TO CITE THIS ARTICLE:

Bailey, J and Kempner, J. 2023. Correction: Standards Without Labs: Drug Development in the Psychedelic Underground. *Citizen Science: Theory and Practice*, 8(1): 49, pp. 1–2. DOI: https://doi.org/10.5334/cstp.647

Submitted: 08 June 2023 Accepted: 08 June 2023 Published: 29 June 2023

COPYRIGHT:

© 2023 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.

Citizen Science: Theory and Practice is a peer-reviewed open access journal published by Ubiquity Press.

